A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
NCT #
NCT03785249
Condition(s)
other solid tumors)
Molecular Target(s)
KRAS G12C
Drug Classification(s)
Smal Molecule Inhibitor
Agents(s)
Adagrasib (MRTX849)
Phase(s)
I/II
Mechanism of Action
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).mutation (G12C).
Purpose
- How much of the study drug can be given with an acceptable level of side effects when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- The effects of the study drug (good and bad) when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- How much of the study drug is absorbed into the blood and how fast it is removed when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- If research tests can be used in the future to predict who will benefit from the study drug
- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
- Unresectable or metastatic disease
- Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
- Adequate organ function
- History of intestinal disease or major gastric surgery or inability to swallow oral medications
- Other active cancer
First-line treatment for NSCLC for certain cohorts
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
23-18
LCB84 is an anti-TROP2 ADC
Antibody Drug Conjugate
Not Required
Anal Canal Squamous Cell Carcinoma, Breast, Colorectal, Endometrial, Gastric, Non-Small Cell Lung, osteosarcoma, other solid tumors), Ovarian, Pancreatic
MCD
23-02
anti-GREM1 monoclonal antibody
Monoclonal Antibody
no restriction
Breast, Colorectal, Esophageal, Gastric, Non-Small Cell Lung, other solid tumors), Prostate, Solid Tumors
MCD
22-07
IMM2902 is a bispecific antibody designed to bind to and block CD47, a cell surface protein that inhibits the immune response, and also bind to...
bispecific antibody
Yes
Breast, Gastric/GEJ (Gastroesophageal Junction)/Esophageal, other solid tumors)
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.